PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 10 | 2 | 150-156
Article title

Znaczenie prognostyczne komórek immunokompetentnych naciekających guzy nowotworowe w rakach narządu płciowego

Content
Title variants
EN
Prognostic signifi cance of tumor infi ltrating lymphocytes in gynecologic cancers
Languages of publication
EN
Abstracts
EN
An interesting field of research in tumor immunology are T-lymphocytes and NK-cells in the area directly adjacent to tumor, i.e. tumor-infiltrating lymphocytes (TIL). An important indicator of immune control of cancer cells is the correlation between intensity of TIL infiltrate and clinical course of the disease. The aim of this paper is a review of particular types of immunocompetent cell infiltrating the tumor and a review of English literature as to data concerning prognostic significance of TIL subpopulations in ovarian, endometrial, cervical and vulvar cancer. Material and method: the PubMed database was searched using key words: CD8+, CD4+, FOXP3+, CD57+, CD56+, NK, combined with phrases: cervical cancer, vulvar cancer, ovarian cancer, endometrial cancer and prognosis. Results: Most important TILs include cytotoxic T-lymphocytes, mostly represented by the CD8+ population, helper T-lymphocytes, designed as CD4+ cells, regulatory lymphocytes Treg, where the most specific maker is transcription regulator forkhead box P3(FOXP3), and NK/NKT cells (naturalkiller/natural killer T-lymphocytes), identified by CD56 and CD57. A close correlation was found between patients’ survival and intensity of infiltrate by CD8+ cells and indicators CD8+/FOXP3+, CD8+/CD4+ and ovarian cancer, endometrial cancer and cervical cancer. An exception to this is vulvar cancer, where CD8+, CD4+ and FOXP3+ have no prognostic significance. Conclusions: Severity of local cytolysis of tumors and inhibition of immunosuppressive activity of regulator cells may be used in future therapeutic strategies in patients with ovarian, endometrial and cervical cancer. In vulvar cancer we should rather focus on non-specific immune response for tumor control.
PL
W immunologii nowotworów szczególną uwagę zwraca się na limfocyty T i komórki NK z bezpośredniego otoczenia guza, tzw. limfocyty naciekające guz, czyli komórki TILs (tumor-infiltrating lymphocytes). Ważnym dowodem na nadzór układu odpornościowego nad komórkami raka jest korelacja pomiędzy intensywnością nacieków komórek TILs a przebiegiem choroby. Celem pracy było scharakteryzowanie poszczególnych typów komórek immunokompetentnych, które mogą uczestniczyć w naciekaniu guzów nowotworowych, oraz przeanalizowanie publikacji anglojęzycznych pod kątem danych dotyczących znaczenia prognostycznego subpopulacji TILs w raku jajnika, trzonu macicy, szyjki oraz sromu. Materiał i metoda: Baza PubMed została przeszukana przy użyciu słów kluczowych: CD8+, CD4+, FOXP3+, CD57+, CD56+, NK w połączeniu z frazami: cervical cancer, vulvar cancer, ovarian cancer, endometrial cancer oraz ze słowem prognosis. Wyniki: Do najważniejszych TILs należą cytotoksyczne limfocyty T, w większości reprezentowane w badaniach przez populację komórek CD8+, pomocnicze limfocyty T, oznaczane jako komórki CD4+, limfocyty regulatorowe Tregs, dla których najbardziej specyficznym markerem jest regulator transkrypcji forkhead box P3 (FOXP3), oraz komórki NK/NKT (natural killer/natural killer T lymphocytes), identyfikowane za pomocą CD56 i CD57. W raku jajnika, endometrium oraz szyjki macicy wykazano silny związek pomiędzy czasem przeżycia pacjentów a intensywnością nacieków z komórek CD8+ oraz wskaźnikami CD8+/FOXP3+, CD8+/CD4+. Wyjątek stanowi rak sromu, w którym komórki CD8+, CD4+, FOXP3+ nie posiadały znaczenia prognostycznego. Wnioski: Nasilanie lokalnej cytolizy guzów, a także hamowanie immunosupresyjnego działania komórek regulatorowych może być w przyszłości wykorzystane w strategiach terapeutycznych w raku jajnika, endometrium oraz szyjki macicy. W raku sromu należy ocenić udział komórek nieswoistej odpowiedzi immunologicznej w zwalczaniu guzów nowotworowych.
Discipline
Year
Volume
10
Issue
2
Pages
150-156
Physical description
Contributors
  • Katedra i Klinika Chirurgii Onkologicznej, Gdański Uniwersytet Medyczny. Kierownik Katedry i Kliniki: prof. dr hab. n. med. Janusz Jaśkiewicz
References
  • 1. Jakóbisiak M., Lasek W.: Immunologia nowotworów. W: Gołąb J., Jakóbisiak M., Lasek W., Stokłosa T. (red.): Immunologia. Wydawnictwo Naukowe PWN, Warszawa 2008: 478-495.
  • 2. Cho Y., Miyamoto M., Kato K. i wsp.: CD4+ and CD8+ T cell cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res. 2003; 63: 1555-1559.
  • 3. Dadabayev A.R., Sandel M.H., Menon A.G. i wsp.: Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol. Immunother. 2004; 53: 978-986.
  • 4. Dorothée G., Vergnon I., El Hage F. i wsp.: In situ sensory adaptation of tumor-infiltrating T lymphocytes to peptide- MHC levels elicits strong antitumor reactivity. J. Immunol. 2005; 174: 6888-6897.
  • 5. Ikeguchi M., Hirooka Y.: Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie 2005; 28: 255-259.
  • 6. Kim J.W., Tsukishiro T., Johnson J.T., Whiteside T.L.: Expression of pro- and antiapoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2004; 10: 5101-5110.
  • 7. Kim J.W., Wieckowski E., Taylor D.D. i wsp.: Fas ligand-positive membranous vesicles isolated from sera of patients with oralcancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 2005; 11: 1010-1020.
  • 8. van Herpen C.M., van der Laak J.A., de Vries I.J. i wsp.: Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin. Cancer Res. 2005; 11: 1899-1909.
  • 9. Kimura H., Dobrenkov K., Iida T. i wsp.: Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells. Anticancer Res. 2005; 25: 85-94.
  • 10. Kuss I., Hathaway B., Ferris R.L. i wsp.: Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv. Otorhinolaryngol. 2005; 62: 161-172.
  • 11. Zou W.: Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006; 6: 295-307.
  • 12. Barnet B., Kryczek I., Cheng P. i wsp.: Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. 2005; 54: 369-377.
  • 13. Zheng Y., Rudensky A.Y.: Foxp3 in control of the regulatory T lineage. Nat. Immunol. 2007; 8: 457-462.
  • 14. Kopeć-Szlęzak J., Podstawka U.: Biologia komórek NK (Natural Killer). Onkol. Pol. 2007; 10: 115-119.
  • 15. Kuss I., Hathaway B., Ferris R.L. i wsp.: Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2004; 10: 3755-3762.
  • 16. Orlando L., Renne G., Rocca A. i wsp.: Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. Ann. Oncol. 2005; 16: 1094-1099.
  • 17. Naito Y., Saito K., Shiiba K. i wsp.: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58: 3491-3494.
  • 18. Nakano O., Sato M., Naito Y. i wsp.: Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001; 61: 5132-5136.
  • 19. Schumacher K., Haensch W., Röefzaad C., Schlag P.M.: Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res. 2001; 61: 3932-3936.
  • 20. Zhang L., Conejo-Garcia J.R., Katsaros D. i wsp.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003; 348: 203-213.
  • 21. Callahan M.J., Nagymanyoki Z., Bonome T. i wsp.: Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin. Cancer Res. 2008; 14: 7667-7673.
  • 22. Sato E., Olson S.H., Ahn J. i wsp.: Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 2005; 102: 18538-18543.
  • 23. Hamanishi J., Mandai M., Iwasaki M. i wsp.: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 2007; 104: 3360-3365.
  • 24. Tomsova M., Melichar B., Sedlakova I., Steiner I.: Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol. Oncol. 2008; 108: 415-420.
  • 25. Han L.Y., Fletcher M.S., Urbauer D.L. i wsp.: HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin. Cancer Res. 2008; 14: 3372-3379.
  • 26. Leffers N., Gooden M.J., de Jong R.A. i wsp.: Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother. 2009; 58: 449-459.
  • 27. Clarke B., Tinker A.V., Lee C.H. i wsp.: Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod. Pathol. 2009; 22: 393-402.
  • 28. Stumpf M., Hasenburg A., Riener M.O. i wsp.: Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br. J. Cancer 2009; 101: 1513-1521.
  • 29. Adams S.F., Levine D.A., Cadungog M.G. i wsp.: Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009; 115: 2891-2902.
  • 30. Yamagami W., Susumu N., Tanaka H. i wsp.: Immunofluorescence- detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int. J. Gynecol. Cancer 2011; 21: 1628-1634.
  • 31. de Jong R.A., Leffers N., Boezen H.M. i wsp.: Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol. Oncol. 2009; 114: 105-110.
  • 32. Kondratiev S., Sabo E., Yakirevich E. i wsp.: Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin. Cancer Res. 2004; 10: 4450-4456.
  • 33. Ino K., Yamamoto E., Shibata K. i wsp.: Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin. Cancer Res. 2008; 14: 2310-2317.
  • 34. Chang W.C., Li C.H., Huang S.C. i wsp.: Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma. Cancer 2010; 116: 5777-5788.
  • 35. Shah W., Yan X., Jing L. i wsp.: A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol. Immunol. 2011; 8: 59-66.
  • 36. Nedergaard B.S., Ladekarl M., Thomsen H.F. i wsp.: Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. Br. J. Cancer 2007; 97: 1135-1138.
  • 37. Piersma S.J., Jordanova E.S., van Poelgeest M.I. i wsp.: High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007; 67: 354-361.
  • 38. Sheu B.C., Hsu S.M., Ho H.N. i wsp.: Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. Cancer 1999; 86: 1537-1543.
  • 39. Bethwaite P.B., Holloway L.J., Thornton A., Delahunt B.: Infiltration by immunocompetent cells in early stage invasive carcinoma of the uterine cervix: a prognostic study. Pathology 1996; 28: 321-327.
  • 40. Chao H.T., Wang P.H., Tseng J.Y. i wsp.: Lymphocyte-infiltrated FIGO Stage IIB squamous cell carcinoma of the cervix is a prominent factor for disease-free survival. Eur. J. Gynaecol. Oncol. 1999; 20: 136-140.
  • 41. Sznurkowski J.J., Zawrocki A., Emerich J., Biernat W.: Prognostic significance of CD4+ and CD8+ T cell infiltration within cancer cell nests in vulvar squamous cell carcinoma. Int. J. Gynecol. Cancer 2011; 21: 717-721.
  • 42. Sznurkowski J.J., Żawrocki A., Emerich J. i wsp.: Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests. Gynecol. Oncol. 2011; 122: 307-312.
  • 43. de Jong R.A., Toppen N.L., Ten Hoor K.A. i wsp.: Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma. Gynecol. Oncol. 2012; 125: 186-193.
  • 44. Hakim F.T., Flomerfelt F.A., Boyiadzis M., Gress R.E.: Aging, immunity and cancer. Curr. Opin. Immunol. 2004; 16: 151-156.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-b0a756d8-d19b-4656-95d2-d9a31b3d4d03
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.